US2012277166A1PendingUtilityA1
Conotoxin peptides useful as inhibitors of neuronal amine transporters
Est. expiryOct 2, 2018(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/04A61P 9/00A61P 9/06A61P 29/02A61P 25/24A61P 29/00A61P 25/34A61P 25/22A61P 25/00A61P 13/02A61P 13/00A61K 38/00C07K 7/08C07K 14/43504
46
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.
Claims
exact text as granted — not AI-modified1 - 6 . (canceled)
7 . An isolated, synthetic or recombinant χ-conotoxin peptide having the activity inhibiting a neuronal amine transporter, wherein said χ-conotoxin peptide comprises MrIA as set forth in SEQ ID NO: 1 (NGVCCGYKLCHOC) or a modified sequence of SEQ ID NO: 1 which has undergone a conservative substitution of an amino acid residue, wherein “◯” represents 4-hydroxyproline, and wherein the first and fourth cysteine residues of SEQ ID NO: 1 are connected to form a disulfide bond and the second and third cysteine residues of SEQ ID NO: 1 are connected to form a disulfide bond.
8 . The χ-conotoxin peptide according to claim 7 having the ability to inhibit a neuronal noradrenaline transporter.
9 . The χ-conotoxin peptide according to claim 8 which is a selective inhibitor of neuronal noradrenaline transporter.
10 . The χ-conotoxin peptide according to claim 8 having negligible or no anticholinergic effect.
11 . The χ-conotoxin peptide according to claim 8 having negligible or no activity as a sodium channel blocker.
12 . The χ-conotoxin peptide according to claim 8 having negligible or no activity as an inhibitor of dopamine transporter.
13 . (canceled)
14 . A composition comprising a χ-conotoxin peptide and a pharmaceutically acceptable carrier or diluent, wherein said χ-conotoxin peptide is a peptide according to claim 7 .
15 . The composition according to claim 14 which is a pharmaceutical composition.
16 - 17 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.